Humalog Kwikpen (Insulin Lispro)

Humalog KwikPen is indicated for the management of blood glucose in adults and children with diabetes when rapid insulin action is required.

• Mealtime (prandial) insulin to control post‑meal glucose spikes in type 1 diabetes.
• Mealtime insulin to control post‑meal glucose spikes in type 2 diabetes.
• Supplemental insulin for correction of unexpected hyperglycemia.
• Use in insulin pump transition periods when a rapid‑acting bolus is needed.
• Part of a basal‑bolus regimen combined with a long‑acting insulin.
• Administered subcutaneously 15 minutes before, immediately before, or within 20 minutes after the start of a meal.
• Dose can be adjusted based on carbohydrate intake, pre‑meal glucose level, and individual insulin sensitivity.

• Insulin lispro is a rapid‑acting insulin analog that differs from human insulin by two amino‑acid substitutions, reducing hexamer formation. After subcutaneous injection, the monomeric form is rapidly absorbed into the bloodstream, where it binds to insulin receptors on muscle and adipose cells. Receptor activation stimulates the phosphatidylinositol‑3‑kinase pathway, increasing GLUT‑4 translocation and glucose uptake, while simultaneously suppressing hepatic gluconeogenesis, leading to a prompt reduction in plasma glucose.

The most frequently reported reactions to Humalog KwikPen are related to the injection site or to systemic insulin activity.

Common

• Mild hypoglycemia, especially if a meal is missed or delayed.
• Redness, swelling, or itching at the injection site.
• Small bruising or bleeding under the skin.
• Transient weight gain due to fluid retention.
• Lipodystrophy (localized thickening or loss of subcutaneous fat) with repeated injections in the same area.
• Transient headache or dizziness, often linked to low blood glucose.

Serious

• Severe hypoglycemia with loss of consciousness or seizures.
• Allergic reaction such as hives, angioedema, or anaphylaxis.
• Injection‑site infection presenting with warmth, pain, and purulent discharge.

When using Humalog KwikPen, clinicians and patients should observe several safety considerations to minimize risks and ensure optimal glucose control.

• Verify the correct pen, dosage, and expiration date before each injection.
• Rotate injection sites within the abdomen, thigh, or upper arm to reduce lipodystrophy.
• Adjust dose in renal or hepatic impairment, as insulin clearance may be reduced.
• Monitor blood glucose frequently during illness, pregnancy, or changes in physical activity.
• Do not share the pen with another person to avoid cross‑contamination.
• Store the pen at controlled room temperature; discard after 28 days once in use.

Humalog KwikPen can interact with other medicines or substances that affect blood glucose levels or insulin metabolism.

Avoid

• Concurrent use of other rapid‑acting insulins or insulin secretagogues without dose adjustment, which may cause severe hypoglycemia.
• Administration of glucagon‑like peptide‑1 (GLP‑1) receptor agonists at high doses that can unpredictably alter insulin requirements.
• High‑dose thiazide diuretics may raise blood glucose and counteract insulin effect.

Use with caution

• Beta‑blockers may mask hypoglycemia symptoms; monitor glucose closely.
• Corticosteroids can increase insulin resistance, requiring higher insulin doses.
• Oral contraceptives or hormone replacement therapy may modestly affect insulin sensitivity.
• Alcohol consumption can cause delayed hypoglycemia; advise patients to monitor glucose for several hours after drinking.